On May 22, 2020, Kintor Pharmaceutical Limited (stock code: 9939. HK) was officially listed on the Hong Kong Stock Exchange. We medicilon extend the congratulations and best wishes.
Medicilon has joined hands with in multiple pharmaceutical development projects in recent years, including external preclinical pharmacokinetic studies and safety evaluation of the androgen receptor antagonist Frestatin (KX-826) and related trials of other drug compounds. The PK and safety evaluation tests of KX-826 completed by Medicilon supports both FDA and NMPA IND filing. In addition, the drug safety evaluation of KX-826 is carried out using mini-pigs as the test species, supporting all stages from preclinical to phases I, II and III clinical trials.